The development of molecular analysis in recent years has provided novel and important indicators for the prognosis of acute myeloid leukemia (AML). Internal tandem duplications (ITDs) in the FMS-like tyrosine kinase-3 (FLT3) gene, partial tandem duplications in the mixed lineage leukemia gene (MLL) and enhanced expression of replication factor ectopic virus integration site 1 are all indicators of poor prognosis. In turn, mutation in replication factor CCAAT/enhancer-banding protein α (CEBPA) is associated with good response to therapy. With current karyotyping methods, no chromosomal abnormality is found in 40% to 50% of AML patients, and differentiation between different prognostic subtypes in this group of patients by present approaches to molecular genetics seems to be of great importance. The majority of these cases are characterized as “AML not otherwise characterized” by the WHO categorization. The findings of a recent study conducted by Falini et al on mutations in exon 12 of the nucleophosmin (NPM1/B23) coding gene in chromosomal location 5q35 showed that NPM1 mutations occur in 35.2% of primary AML cases and these mutations are associated with such features as having a high incidence in all morphologic subtypes of AML (the highest frequency was seen in monocytic leukemias), an absence of hematopoietic stem cell markers like CD34 and CD133, a normal karyotype and responsiveness to chemotherapy.
NPM1 is a phosphoprotein with high expression in proliferating cells and a member of the nucleoplasmic (NPM) family of proteins that is normally localized in nucleolus. Several functions have already been described for NPM1 protein, including binding to nucleic acids, regulation of centrosome duplication and also ribosomal function. Furthermore, NPM1 binds to several proteins, like p53 and proteins that react to and regulate p53 (like Rb, p19ARF and HDM2). The high frequency of NPM1 mutations in normal-karyotype AMLs and the fact that cytoplasmic NPM1 fails to carry out its normal functions such as binding to proteins and transferring them lead to the hypothesis that mutations in NPM1 would be a primary event in leukemogenesis. Therefore, it seems that NPM1 mutations lead to acquiring additional genetic changes in AML leukemic cells. Moreover, NPM1 mutations often occur in association with FLT3/ITD mutations. FLT3 is a receptor tyrosine kinase with important roles in hematopoietic stem/progenitor cell survival and proliferation.

The purpose of this study was the assessment of the frequency and sequence of NPM1 mutations among Iranian AML patients, the detection of the frequency of FLT3/ITD mutations in this group and to examine the relationship between these mutations and the FAB (French-American-British classification) subtypes of AML.

PATIENTS AND METHODS

Bone marrow and peripheral blood samples of 131 AML patients (mean age, 45.9 years; male-to-female ratio, 1.57) were randomly taken at the time of diagnosis and before administration of chemotherapy from the Iranian Blood Transfusion Organization (IBTO) and Hematology-Oncology and Stem Cell Transplantation Research Center of Shariati Hospital (Tehran, Iran). The Medical Ethics Committee of the Iran University of Medical Sciences (IUMS) approved the study (project number P-516), and written informed consent of all patients who participated was obtained.

Blasts and mononuclear cells were purified by Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden) centrifugation and their DNA was extracted by the standard method. Diagnoses were done through morphologic, cytochemical and immunophenotypic assessments by flow cytometry and the patients classified according to FAB criteria. To screen the NPM1 mutations, polymerase chain reaction (PCR) amplification of NPM1 exon 12 was carried out using primers NPM1–F (5'-GCAATTAGGTGAAAGCCAGC-3') and NPM1–R (5'-CAAGACTATTGTGGCTATCCTAAAC-3'), as described in previous studies. The total reaction volume of 50 µL contained approximately 100 ng DNA, 10 pmol of each primer, deoxynucleoside triphosphates (dNTPs, 10 mM each), 2.5 U Prime Taq polymerase and reaction buffer (GENET BIO, Korea) and ddH2O. Samples were amplified using the following PCR conditions: 95°C for 5 minutes; 40 cycles of 94°C for 30 seconds; 55°C for 1 minute; 72°C for 1 minute and finally 72°C for 7 minutes (Techne TC-512). PCR products were visualized by agarose gel electrophoresis with a suitable gene ruler (Gene Ruler 50-bp DNA ladder) to confirm the amplification of fragment of concern (560 bp). Samples were then put in a conformation-sensitive gel electrophoresis (CSGE) program at 95°C for 5 minutes (denaturizing); 65°C for 30 minutes (annealing). To determine any probable homozygote mutations, samples were mixed in pairs and run under the CSGE program. Then, all the products were subjected to electrophoresis under 350 V for 4 hours on 10% CSGE gel. Finally, the CSGE gel was stained with ethidium bromide and exposed to UV light to screen the samples carrying mutation base on different electrophoretic bands (Figure 1). PCR products screened by CSGE technique were purified (AccuPrep PCR purification kit, BioNEER, Korea) and then directly sequenced using NPM1–F and NPM1–R primers (3730XL DNA analyzer, Labège, France).

All DNA samples were then amplified with a PCR step specific to FLT3 gene using primers FLT3/ITD-F (5'-GCAATTAGGTGAAAGCCAGC-3') and FLT3/ITD-R (5'-CTTTCAAGCTTTTGAAGCAG-3') and their PCR products were subjected to electrophoresis on 2.5% agarose gel (100 V for 1 hour) to screen FLT3/ITD mutations (Figure 2). The Fisher exact test was applied to estimate the association between NPM1 and FLT3/ITD mutations.

RESULTS

Among the 131 AML patients who participated in this study, (17.55%) patients (0.95% CI=0.107-0.244) had NPM1 mutations. The presence of these mutations was confirmed using the sequencing technique. Table 1 shows the FAB subtypes among the 23 cases with NPM1 and FLT3/ITD mutations. Among the 23 patients with NPM1 mutation, 14 (60.8%) patients had the mutant allele A, 5 (21.7%) patients had allele D, and 4 (17.4%) patients had allele B. Mutations of NPM1 were heterozygous in all 23 screened patients (Figure 3, Table 2). Of 131 patients, 21 (16.03%) patients (0.95% CI=0.092-0.229) had FLT3/ITD mutations, among whom 2 patients had M1 (9.52%); 5 patients, M2 (23.8%); 7 pa-
Table 1. NPM1 and FLT3/ITD mutations in patients with AML.

| FAB subtypes | All samples (%) | NPM1+ (%) | FLT3 ITD+ (%) | NPM1+/FLT3 ITD+ (%) |
|--------------|-----------------|-----------|---------------|---------------------|
| M0           | 3 (2.2)         | 1 (4.34)  | 0             | 0                   |
| M1           | 17 (12.97)      | 1 (4.34)  | 2 (9.52)      | 0                   |
| M2           | 40 (30.53)      | 4 (17.39) | 5 (23.80)     | 1 (12.5)            |
| M3           | 30 (22.9)       | 4 (17.39) | 7 (33.33)     | 2 (25)              |
| M3v          | 1 (0.76)        | 1 (4.34)  | 1 (4.76)      | 0                   |
| M4           | 29 (22.13)      | 7 (30.43) | 5 (23.8)      | 3 (37.5)            |
| M5           | 9 (6.87)        | 4 (17.39) | 0             | 2 (25)              |
| M6           | 1 (0.76)        | 1 (4.34)  | 1 (4.76)      | 0                   |
| M7           | 1 (0.76)        | 0         | 0             | 0                   |
| Total        | 131             | 23        | 21            | 8                   |

Table 2. Inserted nucleotides in NPM1 exon 12 mutations.

| Wild type (forward sequence) ← | A | C | G | G | T | C | C | T | A | G | A | A | C | T | T |
| Wild type (reverse sequence) → | T | G | C | C | A | G | A | G | T | C | T | T | G | A | A |
| Allele A (forward sequence) ← | A | C | G | G | T | C | C | T | G | T | C | T | C | T | A | G | A |
| Allele A (reverse sequence) → | T | G | C | C | A | G | A | C | A | G | A | G | A | T | C | T |
| Allele B (forward sequence) ← | A | C | G | G | T | A | C | G | T | C | T | C | T | A | G | A |
| Allele B (reverse sequence) → | T | G | C | C | A | T | G | C | A | G | A | G | A | T | C | T |
| Allele D (forward sequence) ← | A | C | G | G | T | C | C | G | T | C | T | C | T | A | G | A |
| Allele D (reverse sequence) → | T | G | C | C | A | G | G | C | A | G | A | G | A | T | C | T |

Inserted nucleotides marked with bold characters. Symbols ← and → show direction of nucleotides.

DISCUSSION
The high frequency of NPM1 mutations among AML patients and their prognostic value underscore the importance of screening for these mutations. Different methods have been described so far to screen and assess NPM1 mutations. These include use of monoclonal antibodies and immunohistochemistry, denaturing high-performance liquid chromatography (DHPLC), capillary electrophoresis of multiplex PCR products, and also fluorescence resonance energy transfer (FRET). In our study, the conformation-sensitive gel electrophoresis (CSGE) technique was used to screen AML patients with NPM1 mutations. The advantage of low cost, easy application and the existence of reports implying adequate sensitivity of this
technique in mutation detection, as well as the absence of any existing report describing screening NPM1 mutations by CSGE—all convinced the researcher to use this technique.

In the study by Falini et al, 38% of AML patients had normal karyotype, among whom 61.7% had NPM1 mutations. The total frequency of NPM1 mutations among all AML cases in this study was reported to be 35.2%. In the study by Thiede et al, the frequency of NPM1 mutations among all AML cases was reported as 27.4%. In the study by Zhang et al, 14.3% of AML patients with normal karyotype were reported to have a mutant NPM1. The other results were different: 24.9% in all AML cases, 74.3% in normal-karyotype AMLs, or 52.9% in normal-karyotype AMLs. In fact, in spite of relative differences in frequencies of these mutations, all studies imply a higher frequency of NPM1 mutations in AML cases with normal karyotype.

In our study, NPM1 gene mutations were detected in 17.5% of AML cases. Due to the unavailability of karyotype information for these patients, assessments of the frequency of NPM1 mutations among AML cases with normal or abnormal karyotype in our study was not possible. However, on the basis of previous reports on the higher frequency of cytogenetic abnormalities among Iranian AML patients, it can be said that it is not unlikely that the above-stated fact has accounted for the lower frequency of NPM1 mutations in our results. Falini et al reported NPM1 mutations in AML subtypes based on FAB classification in all subtypes except M3, M4E0 and M7. In the study by Falini et al, the highest frequency was in M5b (87%), whereas the lowest was in M0 (13.6%). In the study by Verhaak et al, the emphasis was on the high rate of NPM1 mutations in M5 and M6 subtypes, and the lower frequency in other subtypes, including M3, but they did not report mutations in M0. In the study by Döhner et al, the highest frequency of NPM1 mutations was reported in M4 and M5. Thiede et al reported on NPM1 mutations mainly in M2, M5a and M5b, but not in the M3 subtype. No mutation was reported in the M3 subtype in the study by Suzuki et al.
Among the interesting points in our results was the high frequency of NPM1 mutations in the M3 (and M3v) subtype (21.7% of all mutations that had been detected), while most of the previous studies have reported a lower frequency of NPM1 mutations in this group of patients. However, the finding of highest frequency of these mutations in the monocytic subtypes of FAB (M4+M5=47.8%) is completely corroborated by other studies.

Several studies emphasize the high frequency of NPM1 mutations in middle-aged adults or more elderly individuals (average age, 58 years) and the rare incidence of mutations in individuals younger than 35 years. In our data, the age pattern for NPM1 mutations in the Iranian context seems similar to that revealed by previous investigations. In other words, there seems to be a direct relationship between increase in age and the NPM1 mutation incidence in AML patients.

Three major types of mutations in the form of insertion/deletion in the c-terminal region of exon 12 in NPM1 gene (in position 960) have been detected: (1) Insertion of 4 nucleotides, like alleles A, B, C and D, which have high frequency. Alleles A and B have been reported to account for 78% and 12% of all NPM1 mutations, respectively. (2) Deletion of 4 or 5 nucleotides and insertion of 9 new nucleotides in that position, like alleles E and F. (3) Deletion of 9 nucleotides and insertion of 14 new nucleotides. All these mutations finally lead to 4 to 5 nucleotides elongation in this region compared with the wild-type allele and a frame shift mutation in C-terminal of the protein (Figure 3, Table 2). In all of these situations, at least one of two tryptophan (W) residues in positions 288 and 290 (WQWRKSL), which are necessary for the nucleolar localization of NPM1, shift into other amino acids. Of 23 patients who had mutant NPM1 in our study, 14 (60.8%) patients had mutant allele A; 5 (21.7%), allele D; and 4 (17.4%), allele B. Our results showed a high frequency of allele D of the mutant NPM1 gene among Iranian AML patients.

Internal tandem duplication of the FLT3 gene is found in nearly 20% of AML and 5% of myelodysplastic syndrome cases. Previous study in Iran showed a frequency of 18% of FLT3/ITD mutations among Iranian AML patients, especially of the M3 subtype. Our results showed 16.0% of all 131 AML patients who participated in our study had FLT3/ITD mutations. The significance of simultaneous assessment of both mutations is due to the fact that most studies show that a favorable prognostic value of NPM1 mutations is only valid in the absence of FLT3/ITD mutations. It has been shown that a NPM1Pos/FLT3-ITDNeg mutations profile represents an independent predictor for a favorable outcome in younger AML patients, especially in those without cytogenetic abnormalities.

In the study by Falini et al., FLT3/ITD mutations in AML patients with a mutant NPM1 gene occurred twice as often as in AML patients with wild-type NPM1, which suggests a relationship between FLT3/ITD and NPM1 mutations in tumor genesis. In our study, there was a high level of association between mutations in NPM1 and FLT3 (ITD) genes, such that FLT3/ITD mutations had occurred in NPM1-positive AMLs three times more than NPM1-negative AMLs (34.78% vs. 12.03%) (Fisher exact test, P=.012). Since we found no false-positive result after sequencing our positive samples (detected by CSGE method), CSGE seems to have enough specificity for screening NPM1 mutations. However, no judgment can be made about the sensitivity of the CSGE method since we had done no sequencing to confirm our results for negative NPM1 mutations. Of course, all major types of NPM1 mutations (alleles A, B and D) were detected by the CSGE method in the current study.

In conclusion, our data showed a high frequency of NPM1 mutations in the monocytic subtypes of AML, as well as a high degree of association between occurrence of NPM1 and FLT3/ITD mutations. Also, the CSGE was found to be a simple and inexpensive test and an acceptable technique to be used in the screening of NPM1 mutations, although further evaluation is needed.

Acknowledgment
We thank our colleagues from Hematology Department and Research Council of Iran University of Medical Sciences (IUMS) to provide grant for this project.
REFERENCES

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-42.
2. Levis M, Small D. FLT3: IDoes matter in leukemia. Leukemia 2003;17:1738-52.
3. Shiah HS, Kuo YF, Tang JL, Huang SY, Yao M, Tsay W, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 2002;16:196-202.
4. Döhner K, Tobis K, Ullrich R, Fröhling S, Benner A, Schlenk RF, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002;20:3254-61.
5. Van Wauwijk van Doorn-Khosrovani SB, Erpelinc C, van Putten WL, Valk PJ, Post-van de Lughtaarde SV, Hack R, et al. High EV1 expression predicts poor survival in acute myeloid leukemia: A study of 319 de novo AML patients. Blood 2003;101:837-45.
6. Preudhomme C, Sagot C, Boissel N, Cayauela JM, Tiguad I, de Bottin S, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 2002;102:2717-23.
7. Van Wauwijk van Doorn-Khosrovani SB, Erpelinc C, Meijer J, Van ostelhoord S, Putten WW, Valk P, et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003;4:31-40.
8. Fröhling S, Schlenk RF, Breittruch J, Benner A, Kreitmeier S, Tobis A, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2003;100:4372-80.
9. Fröhling S, Schlenk RF, Stolze I, Biblmayr J, Benner A, Kreitmeier S, Tobis A, et al. Phosphorylation-dependent migration of retinoic acid protein into the nucleolus triggered by binding to nucleophosmin (B23). Exp Cell Res 2002;276:233-41.
10. Wu MH, Yang BY. UV stimulation of nucleophosmin (B23) expression is an immediate-early gene response induced by damaged DNA. J Biol Chem 2002;277:48234-40.
11. Kurki S, Peltonen K, Laponen L, Khivariju T, Ojala P, Meek D, et al. Nucleolar protein NPM interacts with HD2M2 and protects tumor suppressor protein p53 from HDME2-mediated degradation. Cancer Cell 2004;5:469-75.
12. Verhaak RG, Goudswaard CS, Putten WW, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54.
13. Grisendi S, Pandolfo P. NPM mutations in acute myelogenous leukemia. N Engl J Med 2005;352:291-2.
14. Kiyoi H, Tovutari M, Yokota S, Hamaguchi M, Ohno R, Saito H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which cause constitutive activation of the product Leukemia 1998;12:1337-7.
15. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1982.
16. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 2005;105:2740-6.
17. Ganguly A, Rock MJ, Prokop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded DNA products and DNA fragments: Evidence for solvent induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 1993;90:3253-9.
18. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia. Blood 1999;93:3074-80.
19. Roti G, Rosati R, Bonasso R, Gorello P, Dive R, Martelli M, et al. Denaturing High-Performance Liquid Chromatography A Valid Approach for Identifying NPM1 Mutations in Acute Myeloid Leukemia. J Mol Diagn 2006;8:254-9.
20. Noguera R, Amatunna E, Zangrilli D, Lavor-gna S, Dionis M, Bussciano F, et al. Simultaneous detection of NPM1 and FLT3/ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005;19:1479-82.
21. Grimead W, Walker H, Harrison G, Oliver R, Chatters S, Harrison CJ, et al. The predictive value of hierarchic cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
22. Theophilus BD, Rapley R. PCR mutation detection protocols. 2002;187:137-50.
23. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaih M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20.
24. Zhang Y, Zhang M, Yang X. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 2007;31:109-11.
25. Suzuki T, Kiyoi H, Otsuki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-61.
26. Alcalay M, Tiacci E, Bergomas R, Bigner B, Venturini E, Minardi SF, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc_AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem cell maintenance. Blood 2005;106:899-902.
27. Toegh GH, Najahi AH, Keyhani M. Cytogenetic findings in acute myeloid leukemia. Acta Medica Iranica 2003;41:227-32.
28. Scholl S, Miöge L, Landt O, Loncarevic I, Kunert C, Clement JH, et al. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res 2007;31:1205-11.
29. Zaker F, Mohammadzadeh M, Mohammadi M. Detection of kit and flt3 mutation in AML with different subtypes. Archives of Iranian Medicine 2010;13:121-25.

PCR...